THE RELATIONSHIP BETWEEN URINARY ANDROST-16-EN-3α-OL AND URINARY 11-DEOXY-17-OXOSTEROID EXCRETION

1963 ◽  
Vol 26 (1) ◽  
pp. 149-153 ◽  
Author(s):  
R. D. BULBROOK ◽  
B. S. THOMAS ◽  
B. W. L. BROOKSBANK
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Common Precursor ◽  
Maximum Conversion ◽  
The Relationship ◽  
Very High

SUMMARY 1. There is a very high correlation between the amounts of urinary androstenol and those of dehydroepiandrosterone, androsterone and aetiocholanolone in women with metastatic breast cancer. 2. In spite of this correlation, which implies a common precursor, tritiated dehydroepiandrosterone or testosterone are not metabolized to androstenol at the periphery (maximum conversion: 0·4% of injected dose) in amounts sufficient to account for the urinary androstenol. 3. As a means of evaluating 'androgen status' androstenol assays do not appear to be more useful than those of the 11-deoxy-17-oxosteroids.

scholarly journals Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer

2009 ◽  
Vol 122 (1) ◽  
pp. 211-217 ◽  
Author(s):  
Edoardo Botteri ◽  
Maria Teresa Sandri ◽  
Vincenzo Bagnardi ◽  
Elisabetta Munzone ◽  
Laura Zorzino ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
The Relationship

Abstract P2-15-05: Visualization of the relationship between survival and sequential treatments in metastatic breast cancer

2020 ◽  
Author(s):  
Gabrielle Rocque ◽  
Aidan Gilbert ◽  
Courtney P Williams ◽  
Arie Nakhmani ◽  
Pravinkumar G Kandhare ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Sequential Treatments ◽  
The Relationship

Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1059-1059
Author(s):  
J. Sperinde ◽  
S. Ali ◽  
K. Leitzel ◽  
E. Fuchs ◽  
W. J. Köstler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Clinical Outcomes ◽  
Metastatic Breast ◽  
Primary Breast Tumor ◽  
P Value ◽  
Her2 Expression ◽  
Abrupt Decrease ◽  
Expression Levels ◽  
Very High

1059 Background: Many HER2-positive patients with metastatic breast cancer (MBC) fail to respond to trastuzumab. We previously reported that precise quantitation of HER2 expression (H2T) by the HERmark assay identified a sub-population of IHC 3+, FISH(+) (positive) patients with low H2T levels that responded poorly to trastuzumab (Lipton, San Antonio Breast Cancer Symposium 2008, abs #32). Here we identify a sub-population of FISH(+) patients with very high H2T levels, that experience clinical outcomes that are indistinguishable from those of FISH(-) (negative) patients with low H2T levels. Methods: The HERmark assay was used to measure H2T in formalin-fixed, paraffin-embedded (FFPE) primary breast tumor specimens from 99 women treated with trastuzumab for MBC. Specimens were also tested by central FISH. A sub-population treatment effect pattern plot (STEPP) was generated to examine the progression-free survival (PFS) rate at 12 months after treatment with trastuzumab across the distribution of H2T. Kaplan-Meier (KM) analyses were performed comparing the PFS of FISH(-), H2T low (log10H2T < 1.25) patients with those of FISH(+), H2T high (log10H2T ≥ 1.95) and FISH(+), H2T intermediate (1.25 < log10H2T < 1.95) groups. Cutoffs were identified by lowest p-value in a positional scanning analysis. Results: The PFS rate improved gradually with increasing H2T in STEPP analyses. At the highest levels of H2T, an abrupt decrease in the PFS rate was observed, consistent with a reduction in susceptibility to trastuzumab. KM analyses demonstrated that patients who were FISH(+), H2T intermediate had a significantly longer PFS than patients who were FISH(-), H2T low (median PFS 12.6 vs. 4.5 mos; HR = 0.34; p < 0.0001). Patients that were FISH(+), H2T high experienced a PFS that was no better than patients that were FISH(-), H2T low (median PFS 4.6 vs. 4.5 mos; HR = 0.87; p = 0.68). Conclusions: Precise quantitation of HER2 expression levels allows the identification of multiple sub-populations of HER2(+) patients that have different clinical outcomes on trastuzumab. MBC patients with very high levels of H2T could represent a sub-group with de novo resistance to trastuzumab who may benefit from combined therapy. [Table: see text]

The relationship between age and survival outcomes for eribulin in metastatic breast cancer.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 1060-1060 ◽  
Author(s):  
C. Twelves ◽  
L. T. Vahdat ◽  
J. Cortes ◽  
J. Wanders ◽  
C. E. Dutcus ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Survival Outcomes ◽  
The Relationship

The relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast cancer

2021 ◽  
Vol 38 (1) ◽  
Author(s):  
Emir Celik ◽  
Nilay Sengul Samanci ◽  
Mehmet Karadag ◽  
Nebi Serkan Demirci ◽  
Fuat Hulusi Demirelli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
The Relationship

Visualizing treatment patterns and survival in metastatic breast cancer.

2019 ◽  
Vol 37 (27_suppl) ◽  
pp. 316-316
Author(s):  
Aidan Gilbert ◽  
Courtney Williams ◽  
Pravinkumar Kandhare ◽  
Arie Nakhmani ◽  
Stephen C. Meersman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Targeted Therapy ◽  
Quantitative Methods ◽  
Metastatic Breast ◽  
Treatment Patterns ◽  
Her2 Status ◽  
Duration Of Treatment ◽  
Treatment Sequencing ◽  
The Relationship

316 Background: Optimal treatment sequencing (i.e., the order in which drugs are given) for metastatic breast cancer (MBC) is unknown. We aimed to develop an approach to visualize treatment patterns and survival in MBC. Methods: This retrospective study utilized ASCO’s CancerLinQ Discovery® database generated from electronic health records. Subjects included 3,312 women aged ≥18 years who were diagnosed with and received treatment for MBC after 1980. Hormone receptor (HR) status was determined by concordant diagnosis and treatment records. Human epidermal growth factor (HER2) status was determined by delivery of HER2-targeted therapy. Ordered and administered treatments were included. We created spatiotemporal plots of treatment patterns for HR+/HER2-, HER2+, and triple negative (TN) MBC. Individuals were represented on the Y-axis, and time on the X-axis with development of MBC aligned at time 0. Treatment classes were identified by colors: hormone therapies in shades of red, chemotherapies in shades of blue, HER2-targeted therapies in shades of green, and novel therapies in shades of orange. Concurrent treatments were represented by split bars. An overlaid Kaplan-Meier curve allowed for observations about the relationship between survival and treatment. Results: We developed a novel visualization approach to simultaneously display heterogeneous, longitudinal treatments and survival. Median survival after first documentation of MBC was 3.1 (IQR 1.4-7.2), 1.3 (IQR 0.6-2.8), and 2.6 (IQR 1.0-5.2) years for HR+/HER2-, TN, and HER2+ MBC, respectively. Patients with longer survival often had long duration of initial therapy, suggesting a more indolent or responsive disease. Substantial heterogeneity in treatment sequencing was observed for HR+HER2- and TN cohorts. In the HER2+ cohort, HER2-targeted therapy was commonly administered for the duration of treatment with more homogeneous sequencing. Conclusions: This novel visualization approach allows for observing the relationship between treatment patterns and survival, which is challenging to demonstrate with traditional quantitative methods. This approach can generate hypotheses regarding impact of treatment patterns on survival.

Sign in / Sign up

Export Citation Format

Share Document